SWOG Cancer Research Network
@swog.org
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956. Member NCTN & NCORP. Online at swog.org. @SupportingSWOG.bsky.social partner.
S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis.
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
January 12, 2026 at 2:20 PM
S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis.
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT).
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
January 9, 2026 at 8:35 PM
Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT).
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC
January 8, 2026 at 4:45 PM
Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC
S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
January 6, 2026 at 8:15 PM
S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.
January 2, 2026 at 9:45 PM
#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.
Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next?
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
January 1, 2026 at 6:10 PM
Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next?
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
December 30, 2025 at 3:53 PM
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis.
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
December 29, 2025 at 2:10 PM
S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis.
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC
December 24, 2025 at 4:20 PM
Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
December 23, 2025 at 5:05 PM
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial
December 22, 2025 at 8:05 PM
Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
December 19, 2025 at 4:26 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype.
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
December 19, 2025 at 3:30 PM
#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype.
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT.
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
December 18, 2025 at 3:55 PM
S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT.
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
December 17, 2025 at 8:10 PM
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC
December 16, 2025 at 9:05 PM
Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC
What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
December 15, 2025 at 8:00 PM
What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease
December 12, 2025 at 1:55 PM
Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease
The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
December 11, 2025 at 1:40 PM
The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Focal, non-diffuse carcinoma in situ (CIS) is allowed.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine
swog.org/clinical-trials/S2427
Focal, non-diffuse carcinoma in situ (CIS) is allowed.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine
swog.org/clinical-trials/S2427
December 10, 2025 at 7:50 PM
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Focal, non-diffuse carcinoma in situ (CIS) is allowed.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine
swog.org/clinical-trials/S2427
Focal, non-diffuse carcinoma in situ (CIS) is allowed.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: Daniel A. Hamstra, MD, PhD Baylor College of Medicine
swog.org/clinical-trials/S2427
AL #amyloidosis trial S2213 compares autologous transplant to Dara-VCD consolidation. Also compares post-consolidation #PatientReportedOutcomes for physical function and other #HRQoL measures.
QoL/PRO Co-PI: Terri Parker, MD Yale Cancer Center
SWOG.org/clinical-trials/S2213
QoL/PRO Co-PI: Terri Parker, MD Yale Cancer Center
SWOG.org/clinical-trials/S2213
December 9, 2025 at 7:55 PM
AL #amyloidosis trial S2213 compares autologous transplant to Dara-VCD consolidation. Also compares post-consolidation #PatientReportedOutcomes for physical function and other #HRQoL measures.
QoL/PRO Co-PI: Terri Parker, MD Yale Cancer Center
SWOG.org/clinical-trials/S2213
QoL/PRO Co-PI: Terri Parker, MD Yale Cancer Center
SWOG.org/clinical-trials/S2213
S2427 (BRIGHT) is a study for people who were treated for muscle invasive #BladderCancer — and the cancer shrunk or can’t be found after treatment. The study asks if a drug plus radiation can help prevent bladder removal. Visit SWOG.org/S2427. Or call 1-800-4-CANCER.
December 8, 2025 at 6:05 PM
S2427 (BRIGHT) is a study for people who were treated for muscle invasive #BladderCancer — and the cancer shrunk or can’t be found after treatment. The study asks if a drug plus radiation can help prevent bladder removal. Visit SWOG.org/S2427. Or call 1-800-4-CANCER.
S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit SWOG.org/S2409. Or call 1-800-4-CANCER. #LCSM
December 8, 2025 at 2:40 PM
S2409 (the PRISM trial) is a study for people with extensive stage small cell lung cancer (ES-SCLC). The goal is to match different #SCLC subtypes with the best treatment. Visit SWOG.org/S2409. Or call 1-800-4-CANCER. #LCSM
Enrolling: SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance.
Co-PI: @surbhisidanamd.bsky.social Stanford Medicine
SWOG.org/clinical-trials/S2213
Co-PI: @surbhisidanamd.bsky.social Stanford Medicine
SWOG.org/clinical-trials/S2213
December 5, 2025 at 4:50 PM
Enrolling: SWOG S2213 in newly diagnosed #ALamyloidosis. Daratumumab + VCD induction, then randomization to autologous stem cell transplant or Dara-VCD consolidation. Patients on both arms get dara maintenance.
Co-PI: @surbhisidanamd.bsky.social Stanford Medicine
SWOG.org/clinical-trials/S2213
Co-PI: @surbhisidanamd.bsky.social Stanford Medicine
SWOG.org/clinical-trials/S2213
#Clinicaltrial S2213 asks if a drug combination (called Dara-VCD) or stem cell transplant is better for people with AL #amyloidosis. The trial is for people who haven’t started treatment yet. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER.
December 3, 2025 at 7:50 PM
#Clinicaltrial S2213 asks if a drug combination (called Dara-VCD) or stem cell transplant is better for people with AL #amyloidosis. The trial is for people who haven’t started treatment yet. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER.